OABIHealthcare · BiotechnologyThe 7 Wall Street analysts covering OmniAb, Inc. hold a median 12-month price target of $9 — +121.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 12 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores OmniAb, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (96): Sales and profits are climbing, and climbing faster than before.
Volatility (38): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on OABI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +121.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $11 |
| 7 Aug 2025 | RBC Capital | Maintains | Outperform | — |
| 7 Aug 2025 | RBC Capital | Maintains | Outperform | $4.00 → $3.00 |
| 12 May 2025 | Benchmark | Reiterates | Buy | — |
| 27 Mar 2025 | RBC Capital | Maintains | Outperform | — |
| 20 Mar 2025 | Benchmark | Maintains | Buy | — |
| 19 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2024 | Benchmark | Reiterates | Buy | — |
| 14 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Aug 2024 | Benchmark | Reiterates | Buy | — |
| 16 Aug 2024 | RBC Capital | Reiterates | Outperform | — |
| 12 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2024 | Benchmark | Reiterates | Buy | — |
| 26 Mar 2024 | Truist Securities | Maintains | Buy | — |
| 22 Mar 2024 | Benchmark | Reiterates | Buy | — |
| 21 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Mar 2024 | RBC Capital | Reiterates | Outperform | — |
| 14 Nov 2023 | Benchmark | Reiterates | Buy | — |
| 11 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 May 2023 | Benchmark | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OABI appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, OmniAb, Inc. returned +154.4% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 11% of US stocks
Cheaper than 41% of US stocks
Cheaper than 91% of US stocks
Higher than 96% of US stocks
Higher than 91% of US stocks
Higher than 98% of US stocks
Higher than 17% of US stocks
Higher than 5% of US stocks
Higher than 32% of US stocks
Higher than 28% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
OmniAb, Inc. has a market value of $591.7M and an enterprise value of $558.7M.
Revenue in the twelve months to 30 June 2026: $38.5M. The latest quarter grew 244.2% year on year.
Net income over the same four quarters: −$44.3M, a −115.1% net margin.
Diluted earnings per share, trailing twelve months: $−0.36.
Free cash flow in the twelve months to 30 June 2026: −$18.1M.
Trailing P/E: −7.2×; forward P/E: −13.8× — the forward figure prices analyst consensus estimates, not reported earnings.
OmniAb, Inc. employs 89 people — $432K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own OmniAb, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
OmniAb, Inc. announced that its management will participate in two upcoming investor conferences: the Nasdaq/LD Micro Summit on September 9, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026.
Why it matters — The announcement signals that OmniAb's management will be engaging with the investment community at notable conferences in September 2026.
OmniAb is transitioning from early-stage biotech to a scalable platform, driven by milestone-rich partnerships such as its recent Eli Lilly collaboration. The Lilly deal validates OmniAb's technology, offers high-margin, capital-light economics, and has raised its 2026 cash guidance to $49–$53 million.
Why it matters — A OABI watcher would care because the Lilly partnership signals third-party validation of OmniAb's platform and strengthens its predictable milestone-revenue outlook and cash position.
OmniAb, Inc. (NASDAQ: OABI) raised its 2026 cash and cash equivalents financial guidance following recent technology licensing activity. CEO Matt Foehr stated that recent business development and licensing activity enabled the company to again raise its 2026 financial guidance and significantly increase its cash outlook.
Why it matters — OmniAb watchers would care because the raised 2026 guidance signals improved cash outlook from recent technology licensing activity.
OmniAb announced a global collaboration and license agreement with Eli Lilly and Company for a new ion channel program, leveraging OmniAb's technology platform and expertise in ion channel discovery and screening.
Why it matters — A collaboration with a major pharmaceutical company like Lilly could expand OmniAb's pipeline and validate its ion channel discovery platform.
OmniAb, Inc. held its Q2 2026 earnings conference call, the transcript of which was published by Seeking Alpha. The call covered the company's financial results and operational developments for the quarter.
Why it matters — Earnings call transcripts provide investors and analysts with detailed insight into the company's quarterly financial performance, strategic direction, and management commentary.
The 7 Wall Street analysts covering OmniAb, Inc. have a median 12-month price target of $9, with estimates ranging from $5 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering OmniAb, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OmniAb, Inc. 95 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, OmniAb, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +121.1% from the last close, and Ticker Nerd's factor model ranks OmniAb, Inc. 95 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering OmniAb, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OABI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $11 over the next 12 months.
OmniAb, Inc. returned +154.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
OmniAb, Inc. is a biotechnology company that licenses discovery research technology to pharmaceutical and biotech companies and academic institutions.
The most recent item we track (Business Wire, 26 Aug 2026): "OmniAb to Participate in Upcoming Investor Conferences". OmniAb, Inc. announced that its management will participate in two upcoming investor conferences: the Nasdaq/LD Micro Summit on September 9, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026.
OmniAb, Inc. is a biotechnology company that licenses discovery research technology to pharmaceutical and biotech companies and academic institutions. OmniAb’s platform is designed to support the discovery of next-generation therapeutics by creating and screening diverse antibody repertoires, helping partners identify optimal antibodies and other target-binding proteins for drug development. Its current offerings center on proprietary transgenic animal systems and related discovery tools that enable the generation of fully human antibodies and other therapeutic candidates. The company also provides integrated and customizable solutions that combine biological and computational methods, including antigen design, immunization, high-throughput screening, and data analysis. OmniAb serves a broad range of partners across the life sciences industry, positioning itself as a technology provider in the antibody discovery and biologics research market. Headquartered in Emeryville, California, OmniAb focuses on enabling research programs rather than developing and commercializing its own drugs.
CEO Mr. Matthew W. Foehr · 89 employees · United States · https://www.omniab.com
